ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN
https://doi.org/10.21518/2307-1109-2018-2-68-74
Abstract
The presented material summarizes the main clinical and theoretical data on the peculiarities of atrial fibrillation (AP) flow in combination with diabetes mellitus (DM). This combination, although associated with a lower age than in patients without diabetes, is associated with a higher risk of stroke and systemic embolism and other adverse complications. The material presents the data of the rocket-AF randomized trial subanalysis on the peculiarities of the use of oral anticoagulant - a direct inhibitor of Xa-factor Rivaroxaban in patients with non-valve AF in combination with DM. Comparative efficacy and safety of Rivaroxaban in patients with diabetes were comparable to those in patients without diabetes. Rivaroxaban in patients with diabetes was associated with lower vascular death rates than warfarin. The results of the randomized trial are largely confirmed in several observational studies that reflect actual clinical practice. Thus, it can be affirmed that Rivaroxaban is not only the most commonly used direct oral anticoagulant in russian practice, but can also be widely used in patients with non-valve AF and diabetes to prevent strokes and systemic embolisms.
About the Author
Alexey D. Ehrlich
The Moscow City Clinical Hospital no. 29 named after N.E. Bauman of the Moscow City Health Department
Russian Federation
Russian Federation
Ehrlich Alexey Dmitrievich – Dr. of sci. (Med.), head of the intensive cardiac care unit
tel: +7 (495) 011-02-39
111020, Moscow, Hospital square, 2
References
1. Глобальный доклад по диабету Всемирной организации здравоохранения 2016 года. Доступно по ссылке http://www.who.int/diabetes/global-report/ru/. [World Health organization Global Report on Diabetes 2016. Available at http://www.who.int/diabetes/global-report/ru/.] (In Russ).
2. Frieberg J., Scharling H., Gadsball N. et al. Sex-specific increase in prevalence of atrial fibrillation (the Copenhagen City Heart study). Am J Cardiol. 2003; 92: 1419-1423.
3. Marten S., Keller L., Helmert S., Michalski F., Werth S., Sahin K., Tittl L., Beyer-Westendorf J. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016 May 2; 115(5): 939-49.
4. Huxley R.R., Filion K.B., Konety S., Alonso A. Metaanalysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108: 56–62.
5. Kato T., Yamashita T., Sekiguchi A. et al. What are arrhythmogenic substrates in diabetic rat atira &. J Cardiovasular Electrophysiol. 2006; 17: 890-894:
6. Tadic M., Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Archives of Cardiovascular diseases. 2015; 108(4): 269-276.
7. Lu Z., Liu N., Bai R. et al. HbA1clevels as predictors of ablation outcome in tipe 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz. 2014; 23.
8. Klem I., Wehinger C., Schneider B., Hartl E., Finsterer J., Stollberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev. 2003; 19: 320–328.
9. Du X., Ninomiya T., De Galan B., Abadir E., Chalmers J., Pillai A., Woodward M., Cooper M., Harrap S., Hamet P., Poulter N., Lip G.Y., Patel A. ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009; 30(9): 1128-35.
10. Afkarian M., Sachs M.C., Kestenbaum B.,Hirsch I.B., tuttle K.P. Himmelfarb J.,de Boer I. Kidney Disease and Increased Mortality Risk in type 2 Diabetes. J Am Soc nephrol. 2013 Jan 31; 24(2): 302–308.
11. Olesen J.B., Lip G., Kamper A.L., Hommel K., Køber L., Lane D.A., Lindhardsen J., Gislason G.H. and torp-Pedersen C. stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. N Engl J Med. 2012; 367: 625-635.
12. Lip G., Frison L., Halperin J.L., Lane D.A. Comparative Validation of a novel Risk score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, stroke, Bleeding History or Predisposition, Labile INR, elderly, Drugs/Alcohol Concomitantly) score. JACC. 2011; 57(2): 173-180.
13. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with eACts the task Force for the management of atrial fibrillation of the european society of Cardiology (ESC) Developed with the special contribution of the european Heart Rhythm Association (EHRA) of the ESC. European Heart Journal doi:10.1093/eurheartj/ehw210.
14. Brown J.D., Shewale A.R., Talbert J.C. Adherence to Rivaroxaban, Dabigatran, and Apixaban for stroke Prevention in Incident, treatment-naïve nonvalvular Atrial Fibrillation. J manag Care Spec Pharm. 2016; 22(11): 1319- 29.
15. Patel M.R., Mahaffey K.W., Garg I., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C. et al., For the ROCKET AF Investigators. Rivaroxaban versus Warfarin in nonvalvular Atrial Fibrillation. N Engl J Med. 2011; 365: 883-891.
16. Bansilal S., Bloomgarden Z., Halperin J.L., HeLlkamp A.S., Lokhnygina Y., Patel M.R., BeckeR R.S., Breithardt G., Hacke W., Hankey G.L., Nessel C.C., Singer D.E., Berkowitz S.D., Piccini J.P., Mahaffey K.W., Fox K.A.A., On behalf of the ROCKET AF steering Committee and Investigators. efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban once-daily, oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of stroke and embolism trial in Atrial Fibrillation (ROCKET AF trial). Am Heart J. 2015; 170: 675-682.e8.
17. Peacock W.F., Tamayo S., Sicignano N., Hopf K.P., Yuan Z. and Patel M. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017; 119: 753-759.
18. CoLeman C.I., Bunz T.J., Eriksson D., Meinecke A.-K., Sood N.A. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. diabetic medicine. 2018; 35 (8): 1105-1110.
19. Инструкция к использованию препарата Ксарелто. Доступно по ссылке http://grls.rosminzdrav.ru/Default.aspx. [Instructions for use of Xarelto. Available at http://grls.rosminzdrav.ru/Default.aspx.] (In Russ).
20. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32: 2387–2394.
Review
For citations:
Ehrlich A.D. ATRIAL FIBRILLATION COMBINED WITH DIABETES MELLITUS. POSSIBILITIES OF USING RIVAROXABAN. Aterotromboz = Atherothrombosis. 2018;(2):68-74. (In Russ.) https://doi.org/10.21518/2307-1109-2018-2-68-74
Views:
1268
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 